高级检索

    右美托咪定联合褪黑素对腹腔镜全子宫切除患者术后睡眠障碍的影响

    Effects of dexmedetomidine combined with melatonin on postoperative sleep disturbance in patients undergoing laparoscopic hysterectomy

    • 摘要: 目的 探讨右美托咪定联合褪黑素对腹腔镜全子宫切除患者术后睡眠障碍(postoperative sleep disturbance,PSD)的影响。方法 采用2×2析因试验设计,选取96例择期行腹腔镜全子宫切除手术患者,采用随机数字表法将患者随机分为4组:右美托咪定和褪黑素组、右美托咪定和安慰剂组、褪黑素和生理盐水组、安慰剂和生理盐水组,每组24例。各组均采用静吸复合全身麻醉,给予相应药物。采用圣玛丽医院睡眠问卷(St. Mary's Hospital Sleep Questionnaire, SMH)和疼痛数字评分法(Numerical Rating Scale, NRS)收集患者术前(T0)、手术当天(T1)、术后第1天(T2)、术后第2天(T3)的睡眠评分和疼痛评分;采用匹兹堡睡眠质量指数量表(Pittsburgh sleep quality index,PSQI)和围术期疲劳评测量表(Identity Consequence Fatigue Scale,ICFS)收集患者术后1周睡眠障碍的发生率和疲劳评分;记录术中丙泊酚与瑞芬太尼用量、术后48 h镇痛补救情况、术后住院时长以及术后不良反应发生情况。结果 右美托咪定和褪黑素不存在交互作用(P=0.746)。与生理盐水相比,右美托咪定能显著降低患者PSD的发生率(31.1% vs 61.7%,P =0.003),术后各时点SMH评分显著增高(P<0.05),NRS评分、ICFS评分、镇痛补救比例及呕吐发生率均显著降低(P<0.05);2组术中丙泊酚、瑞芬太尼用量、术后住院时长及其他不良反应无差异(P>0.05)。与安慰剂相比,褪黑素不能降低患者PSD发生率(41.3% vs 52.2%,P=0.296);褪黑素和安慰剂2组在术后SMH评分、NRS评分、ICFS评分、丙泊酚和瑞芬太尼用量、镇痛补救比例、术后住院时长及不良反应发生率差异无统计学意义(P>0.05)。结论 与生理盐水联合褪黑素或安慰剂相比,右美托咪定联合褪黑素或安慰剂能降低腹腔镜全子宫切除患者的PSD发生率,改善患者术后睡眠质量,减轻术后疼痛,降低围术期疲劳评分,减少恶心发生率。

       

      Abstract: Objective To investigate the effects of dexmedetomidine combined with melatonin on the postoperative sleep disturbance (PSD) in patients with laparoscopic hysterectomy. Methods Based on a 2×2 factorial trail design, 96 patients who were scheduled for laparoscopic hysterectomy were divided into four groups according to the random number table method (n=24): a dexmedetomidine and melatonin group, a dexmedetomidine and placebo group, a melatonin and normal saline group, and a placebo and normal saline group. Each group underwent combined intravenous and inhaled anesthesia and were administered with corresponding drugs. Then, the St. Mary's Hospital Sleep Questionnaire (SMH) and Numerical Rating Scale (NRS) were used to evaluate the sleep quality and pain before surgery (T0), on the day of surgery (T1), on the first day after surgery (T2), and on the second day after surgery (T3). The Pittsburgh Sleep Quality Index (PSQI) and Identity Consequence Fatigue Scale (ICFS) were used to evaluate the incidence of PSD and fatigue one week after surgery. Furthermore, intraoperative propofol and remifentanil dosage, postoperative analgesia remedy, the length of hospitalization stay after surgery, and postoperative adverse reactions were recorded. Results There was no interaction between dexmedetomidine and melatonin (P=0.746). Compared with normal saline, dexmedetomidine significantly reduced the incidence of PSD (31.1% vs 61.7%, P=0.003). The dexmedetomidine group presented remarkable increases in SMH score and decreases in NRS score, ICFS, analgesia recovery ratio and the incidence of vomiting incidence at each time point, compared with the normal saline group (P<0.05). There were no differences in propofol and remifentanil dosage, the length of hospitalization stay and other adverse reactions between the two groups (P>0.05). Compared with placebo, melatonin did not reduce the incidence of PSD (41.3% vs 52.2%, P=0.296). There were no significant differences in SMH score, NRS, ICFS, the dosage of propofol and remifentanil, analgesia recovery ratio, the length of hospitalization stay and the incidence of adverse reactions between the melatonin and placebo groups (P>0.05). Conclusions For patients with laparoscopic hysterectomy, dexmedetomidine combined with melatonin or placebo can reduce the incidence of PSD, improve postoperative sleep quality, reduce postoperative pain, reduce perioperative fatigue score, and reduce the incidence of nausea.

       

    /

    返回文章
    返回